Targeting TRPM2 in ROS-Coupled Diseases
AbstractUnder pathological conditions such as inflammation and ischemia-reperfusion injury large amounts of reactive oxygen species (ROS) are generated which, in return, contribute to the development and exacerbation of disease. The second member of the transient receptor potential (TRP) melastatin subfamily, TRPM2, is a Ca2+-permeable non-selective cation channel, activated by ROS in an ADP-ribose mediated fashion. In other words, TRPM2 functions as a transducer that converts oxidative stress into Ca2+ signaling. There is good evidence that TRPM2 plays an important role in ROS-coupled diseases. For example, in monocytes the influx of Ca2+ through TRPM2 activated by ROS contributes to the aggravation of inflammation via chemokine production. In this review, the focus is on TRPM2 as a molecular linker between ROS and Ca2+ signaling in ROS-coupled diseases. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Yamamoto, S.; Shimizu, S. Targeting TRPM2 in ROS-Coupled Diseases. Pharmaceuticals 2016, 9, 57.
Yamamoto S, Shimizu S. Targeting TRPM2 in ROS-Coupled Diseases. Pharmaceuticals. 2016; 9(3):57.Chicago/Turabian Style
Yamamoto, Shinichiro; Shimizu, Shunichi. 2016. "Targeting TRPM2 in ROS-Coupled Diseases." Pharmaceuticals 9, no. 3: 57.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.